The secure way to view our annual materials and to vote online.
MapLight was founded by internationally recognized research leaders in psychiatry and neuroscience to address the lack of available, circuit specific pharmacotherapies for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting them for therapeutic modulation. Utilizing this approach, we have advanced a robust pipeline of product candidates for some of the most challenging central nervous system conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder.